AgomAb Therapeutics NV (NASDAQ:AGMB) Receives Average Recommendation of “Moderate Buy” from Brokerages

AgomAb Therapeutics NV (NASDAQ:AGMB) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $33.00.

A number of analysts recently weighed in on the stock. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target for the company. HC Wainwright assumed coverage on shares of AgomAb Therapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $35.00 target price for the company. Finally, Wall Street Zen lowered AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday.

AgomAb Therapeutics Price Performance

Shares of NASDAQ AGMB opened at $13.68 on Tuesday. AgomAb Therapeutics has a twelve month low of $8.75 and a twelve month high of $17.82. The company has a 50 day moving average price of $12.59.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. As a group, sell-side analysts anticipate that AgomAb Therapeutics will post -1.77 earnings per share for the current year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.